Eight-hundred and thirty-six patients were randomised to therapy at 25 sites in the United States and received at least one dose of loratadine (n = 357), fexofenadine (n = 360) or placebo (n = 119).

Loratadine and fexofenadine were superior to placebo in reducing the symptoms of SAR. Compared with fexofenadine, loratadine provided significantly greater relief in symptoms of SAR at four of the ...